Navigation Links
Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
Date:10/12/2009

nd is invested in more than 50 private companies. The objective of the Novartis Option Fund is to seed innovative companies through initial and follow on investments. The initial investment is coupled with an option to a specific therapeutic program providing early validation for the company's technology by a larger pharmaceutical partner. The Novartis Venture Funds' team of eight investment professionals located in Basel, Switzerland and Cambridge, Massachusetts, brings together extensive expertise in the biotech and pharmaceutical industry and venture capital.

    For more information: http://www.venturefund.novartis.com

    Contact Information:

    Heptares Therapeutics Ltd
    Dr Malcolm Weir
    Phone:  +44(0)1707-358-629
    Mobile: +44(0)7968-947268
    E-mail: malcolm.weir@heptares.com

    Citigate Dewe Rogerson
    Dr Mark Swallow, Dr Chris Gardner
    Phone: +44(0)20-7282-2948
    E-mail: mark.swallow@citigatedr.co.uk


SOURCE Heptares Therapeutics Ltd


'/>"/>
SOURCE Heptares Therapeutics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
2. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
3. Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease
4. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
5. New Oxygen Biotherapeutics, Inc. Investor Presentation Available on Company Website
6. Reportlinker Adds Stem Cell Therapeutics Markets Report
7. Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report
8. Cell Therapeutics Added to the NASDAQ OMX Global Biotechnology Index
9. Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference
10. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
11. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... South San Francisco, CA (PRWEB) March 25, 2015 ... Trial Provide Support for Novel Mechanism of Action ... CA, March 25, 2015 – Cytokinetics, Incorporated (Nasdaq: ... to its fast skeletal muscle troponin activator tirasemtiv ... results from a Phase IIa “Evidence of Effect” ...
(Date:3/25/2015)...  The Technology Association of Georgia ... promotion and economic advancement of Georgia,s ... of its Top 40 Innovative Technology Companies in ... group at the 2015 Georgia Technology Summit (GTS) on ... TAG,S Top 40 Awards recognize Georgia ...
(Date:3/25/2015)... Proove Biosciences , a commercial ... announce the success of their commercially supported symposium, ... Optimize the Management of Pain, at the 31st Annual ... Maryland on Thursday, March 19th, 2015. , ... Lynn Webster , M.D., former Florida Society of ...
(Date:3/25/2015)... (PRWEB) March 25, 2015 ... segmented on the basis of products, technology, ... in this report are radar, laser, infra-red, ... encompassing video guidance systems, terrain mapping systems, ... market data Tables and 60 Figures spread ...
Breaking Biology Technology:Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 2Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 3Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 4Proove Biosciences Hosts Symposium on Incorporating Genetic Testing to Optimize the Management of Pain 2Smart Weapons Market is Estimate to reach $6.1 Billion by 2020 Worth $6.1 Billion by 2020 - New Report by MarketsandMarkets 2Smart Weapons Market is Estimate to reach $6.1 Billion by 2020 Worth $6.1 Billion by 2020 - New Report by MarketsandMarkets 3
... May 25 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. (Nasdaq: BSPM ... Hepatitis B medicine,Xin Aoxing Oleanolic Acid Capsule ("Xin Aoxing"), and a ... assembly of its production line for its proprietary Zushima product. , ... ...
... NEW YORK , May 25, 2010 ... biosensor and microprocessor technologies for use in,portable monitoring devices, ... the overall daily activity level of an individual and ... overweight or obese. The bracelet,designed both for children and ...
... May 25, 2010 t2cure GmbH, a biopharmaceutical,company developing and marketing ... t2c001 has been,certified by the European Medicines Agency (EMA). , ... t2c001 is the ... Therapy Medicinal Products (ATMPs). It is a somatic,cell therapy product derived from ...
Cached Biology Technology:Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 2Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 3Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 4SPO Medical Announces Innovative Wellness Bracelet 2SPO Medical Announces Innovative Wellness Bracelet 3SPO Medical Announces Innovative Wellness Bracelet 4SPO Medical Announces Innovative Wellness Bracelet 5t2cure First Company to Have Quality of Cellular Therapeutic Certified by EMA 2t2cure First Company to Have Quality of Cellular Therapeutic Certified by EMA 3t2cure First Company to Have Quality of Cellular Therapeutic Certified by EMA 4
(Date:3/18/2015)... March 18, 2015 As mobile payments ... revolutionary smart wallets and apps continue to be introduced into ... in the mobile payment industry in focus today are:  NXT-ID, ... (NYSE: BABA ), Apple Inc. (NASDAQ: ... Facebook Inc. (NASDAQ: FB ) NXT-ID, ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation (OTCQX: ... exhibition for service robots ever held in ... place on May 11-13, 2015 at the Javits ... for the event include: Acorn Product Development; Axis ... Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya Systems ...
(Date:3/12/2015)... , March 12, 2015 The mascots ... Brenner Children,s Hospital, part of Wake Forest Baptist Medical ... initiative for the 2015 ACC Men,s Basketball Tournament. Young ... with them and getting their autographs. Brenner ... Baptist. It is the only children,s hospital in northwest ...
Breaking Biology News(10 mins):Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... the parareptiles, a diverse group of bizarre-looking terrestrial vertebrates ... small, slender, agile and lizard-like creatures, while others attained ... and bony spikes on their skulls. The researchers ... by the end-Permian extinction than at any other point ...
... years ago, the understory of late Mesozoic forests was dominated ... Today, only one genus from this group, Equisetum ... a prime candidate for being the oldest extant genus of ... the evolutionary beginnings of the genus Equisetum . Molecular ...
... (SALT LAKE CITY) New findings from University of Utah School of ... in the blood of patients who have chronic fatigue syndrome (CFS). ... study that linked CFS to XMRV. The study, performed by ... Singh, M.D., Ph.D., associate professor of pathology, was published May 4, ...
Cached Biology News:Reptile 'cousins' shed new light on end-Permian extinction 2Newly discovered plant fossil reveals more than age 2Newly discovered plant fossil reveals more than age 3Newly discovered plant fossil reveals more than age 4Comprehensive study finds no link between XMRV retrovirus and chronic fatigue syndrome 2Comprehensive study finds no link between XMRV retrovirus and chronic fatigue syndrome 3
... This antibody recognizes murine IRF7 ... with other related IRF proteins. ... murine IRF7 protein was confirmed ... the 293T cells transfected with ...
Sprague-Dawley rats, 7-8 weeks old, mixed gender; tissue is collected fresh, frozen on dry ice within minutes of sacrifice and stored at -20C; individual tissue weight approx. 0.05 gram....
...
Contains L-glutamine...
Biology Products: